Perspective

Journal of Diabetes Medication & Care

Ethnic Variability in Drug Response: Implications for Personalized Diabetes Therapy

Samuel Okoye*

Dept. of Endocrine Medicine, Lagos Biomedical University, Nigeria

*Author for correspondence: samuel.okoye@lbu.ng

Received: 01-Oct-2025, Manuscript No. jdmc-26-184901; **Editor assigned:** 04-Oct-2025, PreQC No. jdmc-26-184901 (PQ); **Reviewed:** 18-Oct-2025, QC No. jdmc-26-184901; **Revised:** 21-Oct-2025, Manuscript No. jdmc-26-184901 (R); **Published:** 31-Oct-2025, DOI: 10.37532/jdmc.2025.8(5).319-320

Introduction

Individual response to diabetes medications is influenced by a combination of genetic, environmental, and cultural factors. Ethnic variability plays a significant role in determining drug efficacy, pharmacokinetics, and susceptibility to adverse effects. Understanding these differences is essential for tailoring therapy, optimizing glycemic control, and reducing complications in diverse populations. Personalized diabetes management must account for ethnic-specific responses to ensure safety and therapeutic effectiveness [1,2].

Discussion

Genetic polymorphisms affecting drug metabolism, transport, and receptor sensitivity contribute to ethnic variability in pharmacologic response. For example, variations in genes encoding cytochrome P450 enzymes can alter the metabolism of sulfonylureas, DPP-4 inhibitors, and other oral hypoglycemics. Patients from East Asian populations often demonstrate increased sensitivity to sulfonylureas, resulting in greater glucose-lowering effects but higher hypoglycemia risk compared with Caucasian populations. Conversely, some African and Hispanic populations may have reduced response to certain insulin secretagogues, necessitating alternative strategies [3,4].

Ethnic differences also influence the pharmacodynamics of newer therapies. SGLT2 inhibitors, which promote renal glucose excretion, may have variable efficacy based on differences in renal function prevalence, body composition, and baseline glycosuria among populations. GLP-1 receptor agonists demonstrate variable weight loss and glycemic outcomes in different ethnic groups, potentially reflecting genetic, metabolic, or lifestyle factors.

Beyond genetics, environmental and cultural factors modulate drug response. Dietary habits, physical activity, and adherence patterns differ across populations and can influence both efficacy and side-effect profiles. Socioeconomic factors, healthcare access, and cultural perceptions of treatment also affect real-world outcomes, highlighting the need for population-specific education and counseling [5].

Incorporating ethnic variability into clinical decision-making supports precision medicine. Dose adjustments, careful monitoring, and selective drug choice based on population-specific evidence can minimize adverse effects and enhance efficacy. Clinical trials increasingly include diverse populations to capture these differences and inform guideline recommendations.

Conclusion

Ethnic variability in drug response is a critical consideration in diabetes management. Genetic, metabolic, and cultural factors can significantly influence efficacy, safety, and adherence, emphasizing the need for personalized therapy. Recognizing these differences allows clinicians to optimize drug selection, dosing, and monitoring for

diverse populations, improving outcomes and reducing complications. As precision medicine advances, integrating ethnic-specific data into diabetes care will become increasingly essential for equitable and effective treatment.

References

1. Buckley RC, Brough P, Westaway D (2018) Bringing Outdoor Therapies into Mainstream Mental Health. Front Public Health 6:1-19.
2. Balanzá-Martínez V, Cervera-Martínez J (2022) Lifestyle Prescription for Depression with a Focus on Nature Exposure and Screen Time: A Narrative Review. Int J Environ Res Public Health 19:50-94.
3. Johnson EG, Davis EB, Johnson J, Pressley JD, Sawyer S, et al (2020) The effectiveness of trauma-informed wilderness therapy with adolescents: A pilot study. Psychol Trauma 12:878-887.
4. Wentink GH, Edel W (2000) Hazard analysis and critical control point (HACCP) approach and food safety as well as Legislation. Vet Q 22:121.
5. Varzakas TH (2011) Application of ISO22000, failure mode, and effect analysis (FMEA) cause and effect diagrams and Pareto in conjunction with HACCP and risk assessment for processing of pastry products. Crit Rev Food Sci Nutr 51:762-782.